Alcohol Use Disorder (AUD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Alcohol Use Disorder (AUD) Market Outlook

Thelansis’s “Alcohol Use Disorder (AUD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alcohol Use Disorder (AUD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Alcohol Use Disorder (AUD) Overview

Alcohol Use Disorder (AUD) is a pathological condition characterized by persistent and excessive alcohol consumption, leading to a diminished ability to limit or abstain from alcohol use despite adverse consequences in one's social, occupational, or medical domain. The disease is characterized by several key symptoms, including: 1. Craving - an intense urge to consume alcohol 2. Loss of control - an inability to cease alcohol consumption once initiated 3. Negative emotional state - feelings of anxiety and irritability when abstaining from alcohol. Several factors increase the chances of developing an alcohol use disorder, such as Family history of substance abuse and alcohol use disorder, Accessibility of alcohol, Excessive alcohol consumption, Binge drinking, Permissive cultural attitudes towards alcohol, Childhood abuse, Childhood conduct or mood disorders, Co-occurring mental health conditions such as depression and PTSD, Impulsivity. Diagnosis of AUD is made through a comprehensive evaluation and assessment of symptoms, as outlined in the Diagnostic and Statistical Manual of Mental Disorders. The severity of the disorder is determined based on the number of criteria met and can range from mild (2-3 criteria), moderate (4-5 criteria) to severe (6 or more criteria). The U.S. Food and Drug Administration approved three drugs for managing AUD, including naltrexone, acamprosate, and disulfiram, which aid in reducing alcohol consumption and preventing relapse.

• According to a national survey in the USA, 14.1 million adults ages 18 and older (5.6% of this age group) had alcohol use disorder (AUD).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: